NCT00207129View on ClinicalTrials.gov

Effect of Capecitabine on the Pharmacokinetics of BMS-247550 and BMS-247550 on the Pharmacokinetics of Capecitabine and Its Metabolites in Patients With Advanced Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

December 31, 2005

Study Completion Date

December 31, 2005

Conditions
Advanced Solid TumorsNeoplasms
Interventions
DRUG

Ixabepilone

Solution, I.V. infusion, 40 mg/m2, Cycles 1-18: once per cycle (Day 1) cycles 2-18 (6-54 weeks) depending on response.

DRUG

Capecitabine

Tablets, Oral, 1000 mg/m2, Cycle 1: Once (Day 1) Cycle 2: Twice daily (Days 1-5) Cycles 3-18: None, 2 cycles (6 weeks).

Trial Locations (1)

Unknown

Local Institution, San Antonio

Sponsors

Lead Sponsor

R-Pharm
All Listed Sponsors
lead

R-Pharm

INDUSTRY